Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paliperidone palmitate - Johnson & Johnson

Next Previous
Drug Profile

Paliperidone palmitate - Johnson & Johnson

Alternative Names: BYANNLI; Invega Hafyera; Invega Sustenna; Invega Trinza; Paliperidone palmitate 1-month; Paliperidone palmitate 3-month; Paliperidone palmitate 6-month; R0-92670; RO-92670; Sustenna; Trevicta; Xeplion

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johnson & Johnson
  • Developer Janssen; Janssen Pharmaceutical KK; Johnson & Johnson; Xian-Janssen
  • Class 2 ring heterocyclic compounds; Antipsychotics; Fluorobenzenes; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 5-HT2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Schizoaffective disorder; Schizophrenia

Most Recent Events

  • 23 Feb 2023 Alkermes has patent protection for NanoCrystal technology covering INVEGA HAFYERA in USA (Prior to February 2023)
  • 28 Jun 2022 Janssen completes a phase III trial in Schizophrenia in Argentina, Hong Kong, Italy, Poland, Russia and Ukraine (IM) (NCT04072575) (EudraCT2018-004532-30)
  • 23 Nov 2021 Registered for Schizophrenia (Treatment-experienced) in European Union, Iceland, Norway and Liechtenstein (IM)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top